New mRNA shot aims to tame rogue immune cells in stubborn diseases
NCT ID NCT06747156
Summary
This early-stage study is testing a new mRNA-based therapy called ABO2203 in people with autoimmune diseases that haven't responded well to standard treatments. The main goal is to check if the treatment is safe and tolerable, while also looking for early signs that it might help control the disease. The study will test different doses in a small group of 66 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.